ClinicalTrials.gg
Not yet recruitingNCT07559604Updated Oct 16, 2026

The Effects of Mango on Gut Health Markers

An interventional study of Mango in Gut Health, LBP and Short Chain Fatty Acids, sponsored by Loma Linda University. Not yet recruiting at 1 site in United States. Open to participants aged 40 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Loma Linda University · Not applicable, Interventional, and Treatment

How we know

Updated Oct 16, 2026Start date movedPrimary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
40 Years to 60 Years
Sex
All
01

Study summary

This is an ancillary study of NCT06159543, which was a clinical trial that examined the effect of a 12-week 1.5 cups daily mango crossover intervention on cardiometabolic outcomes in individuals with prediabetes, male and female, and 40-60 years of age. The goal of this ancillary study is to test the effect of the mango intervention on gut health markers in individuals with prediabetes. The main questions it aims to answer are:

  1. What is the effect of 1.5 cups per day of fresh mango over 12 weeks on indicators of gut permeability as measured by lipopolysaccharide-binding protein (LBP) and soluble CD14 (sCD14)?
  2. What is the effect of 1.5 cups per day of fresh mango over 12 weeks on microbiome modulation as estimated by short chain fatty acids (SCFAs)?

Secondarily:

  1. Is LBP a mediator of the relationship between systemic inflammation [as determined by C-reactive protein, E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1)] and SCFAs?
  2. Is LBP a mediator of the relationship between insulin resistance [as determined by HOMA-IR] and SCFAs?
  3. Is sCD14 a mediator of the relationship between systemic inflammation [as determined by C-reactive protein, E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1)] and SCFAs?
  4. Is sCD14 a mediator of the relationship between insulin resistance [as determined by HOMA-IR] and SCFAs?

Researchers will compare the 12 weeks participants consume mango to the 12 weeks the participants are not consuming mango to see if there are differences in LBP, sCD14, and SCFAs.

As noted, this is an ancillary study of NCT06159543. Fasting blood was collected at baseline, and at the end of each phase of NCT06159543. This blood will be used to analyze LBP, sCD14 and SCFAs. Fasting blood and insulin were analyzed in NCT06159543, and will used to calculate HOMA-IR in the ancillary study. C-reactive protein, E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) will be analyzed NCT06159543.

02

Conditions studied

  • Gut Health
  • LBP
  • Short Chain Fatty Acids
  • sCD14
03

In context

Lead sponsor

Loma Linda University is the lead sponsor of 306 studies on the registry; 46 are open to participants now.

Of its 29 completed or terminated interventional studies of FDA-regulated products, 23 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participated in NCT06159543

Exclusion criteria

Exclusion Criteria:

  • Did not participate in NCT06159543
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
31 participants (estimated)

Study arms

  • Experimental
    Mango added to habitual diet

    In NCT06159543 participants were asked to consume 1.5 cups of mango per day for 12 weeks as part of their habitual diet.

    Behavioral: Mango

  • No intervention
    Habitual diet without mango

    In NCT06159543 participants were asked to refrain consuming mangoes for 12 weeks while continuing their habitual diet.

Interventions

  • BehavioralMango

    1.5 cups/day of mango for 12 weeks

06

What researchers measure

Primary outcomes

  1. Lipopolysaccharide-binding protein (LBP)

    Lipopolysaccharide-binding protein (LBP) will be measured in fasting blood that was drawn at baseline and the end of each phase of NCT06159543.

    Time frame: From baseline to the end of 8 months

  2. sCD14

    sCD14 will be measured in fasting blood that was drawn at baseline and the end of each phase of NCT06159543.

    Time frame: From baseline to the end of 8 months

  3. Short Chain Fatty Acids (SCFAs)

    Short Chain Fatty Acids (SCFAs) will be measured in fasting blood that was drawn at baseline and the end of each phase of NCT06159543.

    Time frame: From baseline to the end of 8 months

07

Study locations

1 site
  • Nutrition Research Center, School of Public Health, Loma Linda University
    Loma Linda, California 92350, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jan 2027; primary completion for Jun 2027, 5 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: start Sep 2026 → Jan 2027 and primary completion Dec 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2026
First posted
Apr 30, 2026
StartEst.
Jan 2027was Sep 2026
Primary completionEst.
Jun 2027was Dec 2026
CompletionEst.
Dec 2027
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 2026→Jan 2027
Oct 16, 2026
Primary completion
Dec 2026→Jun 2027
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Start date Sep 2026→Jan 2027
    Primary completion Dec 2026→Jun 2027
    + 1 other change: responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07559604
Responsible party
Celine Heskey (Associate Professor, Loma Linda University) — Principal investigator
First posted
Apr 30, 2026
Start date
Jan 2027 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 16, 2026

Study contacts

Amandeep Wright, MPH
Contact
amawright@llu.edu
(909) 558-4300 ext. 47169
Celine Heskey, DrPH
Contact
cheskey@llu.edu
(909) 558-1000 ext. 47181
Celine Heskey, DrPH
principal investigator · Loma Linda University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion